Margaret A.WinklerMDIndividualAuthorPhil B.FontanarosaMD, Senior EditorsIndividualAuthor
Copyright 1999 American Medical Association.
All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999
To the Editor: The timely update by Dr Stern and
colleagues1 on emerging issues in early detection of
prostate and colorectal cancers raised many important points, some of
which require clarification and emphasis.
The American Cancer Society (ACS) recognizes that there exist
differing opinions as to whether early detection testing for prostate
cancer lowers disease-specific mortality. Our updated guidelines of
June 1997 advise physicians and other clinicians to offer
early-detection testing for prostate cancer to appropriate patients and
to provide information to patients on the test's potential risks and
benefits.2 The casual reader of the article by Stern et al
might erroneously construe that ACS supports "mass" screening.
Rosenthal DS, Feldman G. Talking With Patients About Screening for Prostate Cancer. JAMA. 1999;281(2):133. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-2-jac80019